Compare Ascendis Pharma A/S (ASND) vs United Parcel Service Inc (UPS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ascendis Pharma A/S vs United Parcel Service Inc — how do they compare? Ascendis Pharma A/S trades at $264.44 (market cap $17.74B), while United Parcel Service Inc trades at $113 (market cap $95.60B). The key difference: United Parcel Service Inc is far larger — about 5.4× Ascendis Pharma A/S's market cap, and United Parcel Service Inc pays a 5.83% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | UPS | |
|---|---|---|
Market Cap | $17.74B | $95.60B |
Sector | Health | Industrials |
52-Week High | $277.18 | $120.00 |
52-Week Low | $163.32 | $82.58 |
Enterprise Value | $18.11B | $118.46B |
Volume | — | 2,288,643 |
Dividend Yield | — | 5.83% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
UPS trades at $112.47, up 1.56% today, with a bullish technical signal and consistent earnings beats. The stock shows strong profitability with a 33.41% ROE and 5.94% net margin, though revenue has declined from $100.3B in 2022 to $88.66B in 2025. Recent news highlights a $48M investment in healthcare logistics and competition concerns from Amazon's logistics expansion.
Outlook is mixed: valuation appears reasonable with a P/E of 18.2, and analysts give a $112 consensus target, but revenue pressure and competitive threats pose risks. The dividend remains supported by solid cash flow, but growth depends on successful execution in a challenging environment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About United Parcel Service Inc
United Parcel Service, Inc. (UPS) delivers packages and documents throughout the United States and in other countries and territories. The Company also provides global supply chain services and less-than-truckload transportation, primarily in the US UPS's business consists of integrated air and ground pick-up and delivery network
Read more on UPS →
